



**Statement of stand-alone Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2014**

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (REVIEWED)			YEAR-TO-DATE FIGURES (REVIEWED) FOR THE NINE MONTHS PERIOD ENDED ON		YEAR ENDED (AUDITED)
	31-DEC- 2014	30-SEP- 2014	31-DEC- 2013	31-DEC- 2014	31-DEC- 2013	
<b>PART I : STATEMENT OF STAND-ALONE RESULTS</b>						<b>31-MAR-2014</b>
01. Gross Sales / Income from Operations	16093	18677	16227	51720	44083	58960
Less : Excise Duty	160	215	201	717	450	582
Less : Sales Tax	356	351	321	1115	868	1174
Net Sales / Income from Operations	15577	18111	15705	49888	42765	57204
02. Other Operating Income	1119	1017	1718	4084	4146	5029
03. TOTAL INCOME FROM OPERATIONS	16696	19128	17423	53972	46911	62233
04. EXPENDITURE						
a) Cost of materials consumed	4881	3820	4485	12593	12111	16670
b) Purchases of stock-in-trade	-	-	-	-	-	-
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-198	725	-908	1004	-1410	-1597
d) Employee benefits expense	2793	2909	2492	8417	6911	9422
e) Depreciation and amortization expense	1075	1023	686	3117	1983	2679
f) Other Expenses	4432	5586	5531	15026	14304	19080
TOTAL EXPENSES	12983	14063	12286	40157	33899	46254
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3713	5065	5137	13815	13012	15979
06. Other Income	712	300	105	1100	632	1571
07. Profit/(Loss)from ordinary activities before finance Cost and exceptional items	4425	5365	5242	14915	13644	17550
08. Finance costs	811	699	877	2146	2792	3405
09.Profit/(Loss) from ordinary activities after finance Costs but before exceptional items	3614	4666	4365	12769	10852	14145
10. Exceptional Items	1513	-	-	1513	-	-
11. Profit / (Loss) from ordinary activities before tax	2101	4666	4365	11256	10852	14145
12. Tax expense, including deferred tax	440	1186	1123	2475	2467	3126
13. Net Profit / Loss (-) from ordinary activities after tax	1661	3480	3242	8781	8385	11019
14.Extraordinary items (net of tax expenses)	-	-	-	-	-	-
15.Net Profit/(Loss)for the period	1661	3480	3242	8781	8385	11019
16 Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3323	3307	3307	3323	3307	3307
17. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						69983
18. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	5.02 5.02	10.52 10.52	10.14 10.14	26.54 26.54	26.55 26.55	34.49 34.49
<b>Part II : Select Information</b>						
19. Public Shareholding:						
a) Number of Shares	15,373,985	15,373,943	15,311,593	15,373,985	15,311,593	15,365,107
b) Percentage of Shareholding	46.26	46.48	46.30	46.26	46.30	46.46
20 Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered –						
b) Non – encumbered – No. of shares	17,860,864	17,699,131	17,761,481	17,860,864	17,761,481	17,707,967
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	53.74	53.52	53.70	53.74	53.70	53.54

Dated at Hyderabad, this, the 11<sup>th</sup> day of February, 2015  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

  
V.C. Nannapaneni  
Chairman & Managing Director

Status of Investor Complaints as at 31<sup>st</sup> December, 2014

Pending as on 01-10-2014	Nil
Received during the quarter	74
Resolved during the quarter	74
Pending as on 31-12-2014	Nil